Balaxi Pharmaceuticals Ltd (BALAXI)
₹109.2▲1.72%
Performance
Day's Low
Day's High
₹107.35₹110.6152 Week's Low
52 Week's High
₹79.99₹151.45
| Returns % | |
| 1 Month Return | -10.74 % |
| 3 Month Return | -6.1 % |
| 1 Year Return | + 5.04 % |
| Market Stats | |
| Previous Close | ₹107.35 |
| Open | ₹107.90 |
| Volume | 9,986.00 |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹592.65Cr |
Key Statistics
| P/E Ratio | -199.54 |
| PEG Ratio | 20.55 |
| Market Cap | ₹592.65 Cr |
| P/B Ratio | 6.6 |
| EPS | 1.22 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹592.65 Cr | 145.03% | 0.56 | ₹45 Cr | ₹336 Cr |
 | NA | ₹107.89 Cr | 247.39% | 0.51 | ₹2 Cr | ₹75 Cr |
| NA | ₹14.32 Cr | -0.68% | 0.51 | NA | ₹2 Cr |
| NA | ₹88.47 Cr | 66.06% | 0.53 | ₹1 Cr | ₹107 Cr |
| NA | ₹96.22 Cr | 351.91% | 0.87 | NA | NA |
Company Information
In March 2017, Balaxi Overseas Pvt Ltd acquired 16,700,036 (54.94%) equity shares of the company along with its control and management. Its representatives became the new directors and the company was renamed to Balaxi Ventures. A preferential issue of 6,960,000 equity shares was approved in July 2019 and allotted in August, increasing the company’s paid-up share capital to Rs 100,000,000. Following this, Balaxi Ventures started international wholesale trading in pharmaceutical products, builders hardware, and recently launched YAP food products.
Share Price: ₹109.20 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹592.65Cr as of today
Revenue: ₹59.83Cr as on March 2024 (Q1 24)
Net Profit: ₹10.93Cr as on March 2024 (Q1 24)
Listing date: 30 Nov, 2015
Chairperson Name: Ashish Maheshwari
| Organisation | Balaxi Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Trading |
| E-voting on shares | Click here to vote |
Key events for Balaxi Pharmaceuticals Ltd
Balaxi Pharma Jumps on Strategic Partnerships and Tender Business - 25 Jun, 2024
Balaxi Pharmaceuticals Ltd's stock rose by 5.19% following the announcement of its strategic hospital partnerships with approximately 50 hospitals across Angola and securing a tender worth USD 0.8 million in a key Latin American market, marking the company's first foray into the large tender business in Latin America.
Balaxi Pharma Q4 Net Profit Up 34.98% YoY - 13 Jun, 2024
Balaxi Pharma's net profit for the quarter ending March 2024 increased by 34.98% YoY to Rs. 10.93 crore, while net sales decreased by 25.84% YoY to Rs. 59.83 crore. The company's EPS also increased from Rs. 8.01 in March 2023 to Rs. 10.41 in March 2024. Balaxi Pharma shares closed at Rs. 126.78 on June 12, 2024 (NSE) and have given returns of 53.39% over the last 6 months and 18.44% over the last 12 months.
Balaxi Pharma Reports Decrease in Net Sales and Quarterly Net Loss - 05 Jun, 2024
Balaxi Pharmaceuticals reported a decrease of 47.6% YoY in net sales for March 2024, with a quarterly net loss of Rs. 0.58 crore. The company's EBITDA also decreased by 93.37% YoY. Balaxi Pharma shares closed at 97.90 on June 04, 2024 (NSE) and have given returns of 16.98% over the last 6 months and -9.64% over the last 12 months.
Balaxi Pharmaceuticals Reports Net Loss in FY 2024 - 02 Jun, 2024
Balaxi Pharmaceuticals reported a net loss of ₹23.9m in FY 2024, down by 105% from ₹459.6m profit in FY 2023. The revenue for FY 2024 was ₹2.39b, down 29% from FY 2023. Shares are down 7.2% from a week ago.
Balaxi Pharmaceuticals Ltd's Poor Financial Performance Raises Risk - 29 May, 2024
Balaxi Pharmaceuticals Ltd's revenue has been in decline, with a 24% decrease in the last year. Comparing recent medium-term revenue trends against the industry's one-year growth forecast of 20%, it is less attractive and places shareholders at risk.
Insights on Balaxi Pharmaceuticals Ltd
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 66.36% of holdings in Apr 2024 quarter
- NO EFFECT
FII Holding Unchanged
Foreign Institutions holdings remained unchanged at 17.08% of holdings in Apr 2024 quarter
- NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 16.54% of holdings in Apr 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 1 month, BALAXI stock has moved down by -10.7%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 62.29 Cr → 59.14 Cr (in ₹), with an average decrease of 5.1% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 14.43 Cr → 10.93 Cr (in ₹), with an average decrease of 12.7% per quarter
Company Financials
| Q'1 24 | Q/Q Change | |
|---|---|---|
Revenue | ₹59.83Cr | ↓1.58% |
Net Income | ₹10.93Cr | ↓19.57% |
Net Profit Margin | 18.27% | ↓18.29% |
| 2023 | Y/Y Change | |
|---|---|---|
Revenue | ₹336.43Cr | ↑20.42% |
Net Income | ₹45.96Cr | ↓3.57% |
Net Profit Margin | 13.66% | ↓19.93% |
| 2023 | Y/Y Change | |
|---|---|---|
Total Assets | ₹129.73Cr | ↑58.38% |
Total Liabilities | ₹37.62Cr | ↑56.75% |
| 2023 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -₹7.07Cr | ↓179.53% |
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 66.36% | 0.00 | |
| Foreign Institutions | 17.08% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 16.54% | 0.00 | |
| Others | 0.02% | 0.00 |
Key Indicators
Balaxi Pharmaceuticals Ltd Valuation
Balaxi Pharmaceuticals Ltd in the last 5 years
Lowest (-263.96x)
May 28, 2024
Today (-199.54x)
July 23, 2024
Industry (102.57x)
July 23, 2024
Highest (66.45x)
September 21, 2020
Earnings and Dividends
Balaxi Pharmaceuticals Ltd Earnings Results
Balaxi Pharmaceuticals Ltd’s net profit jumped 34.94% since last year same period to ₹10.93Cr in the Q4 2023-2024. On a quarterly growth basis, Balaxi Pharmaceuticals Ltd has generated -19.57% fall in its net profits since last 3-months.
Read More about Earnings ResultsBalaxi Pharmaceuticals Ltd Dividends May,2022
In the quarter ending March 2022, Balaxi Pharmaceuticals Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.47%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Balaxi Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Balaxi Pharmaceuticals Ltd shares.
Balaxi Pharmaceuticals Ltd (BALAXI) share price today is ₹109.2
Balaxi Pharmaceuticals Ltd is listed on NSE
Balaxi Pharmaceuticals Ltd is not listed on BSE
- Today’s highest price of Balaxi Pharmaceuticals Ltd is ₹110.61.
- Today’s lowest price of Balaxi Pharmaceuticals Ltd is ₹107.35.
PE Ratio of Balaxi Pharmaceuticals Ltd is -199.54
PE ratio = Balaxi Pharmaceuticals Ltd Market price per share / Balaxi Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Balaxi Pharmaceuticals Ltd(BALAXI) is 9,986.00.
Today’s market capitalisation of Balaxi Pharmaceuticals Ltd(BALAXI) is ₹592.65Cr.
| Balaxi Pharmaceuticals Ltd(BALAXI | Price |
|---|---|
52 Week High | ₹151.45 |
52 Week Low | ₹79.99 |
Balaxi Pharmaceuticals Ltd(BALAXI) share price is ₹109.2. It is down -27.90% from its 52 Week High price of ₹151.45
Balaxi Pharmaceuticals Ltd(BALAXI) share price is ₹109.2. It is up 36.52% from its 52 Week Low price of ₹79.99
| Balaxi Pharmaceuticals Ltd(BALAXI | Returns |
|---|---|
1 Day Returns | 1.85% |
1 Month Returns | -10.74% |
3 Month Returns | -6.1% |
1 Year Returns | 5.04% |